India’s weight loss category is undergoing a dynamic transformation triggered by scientific improvements, pharma innovation, and growing consumer demand ...

Novo Nordisk is also poised to launch its semaglutide injection Wegovy in India shortly. The drug has also shown cardiovascular benefits in Indian patients. “Rybelsus had propelled the growth of ...

Are we returning to a world where ‘slim’ is yet again being seen as the ideal body image? The concept of the ideal body has ...

Novo Nordisk has said it is discontinuing selling its popular, best-selling insulin brand in India and will instead promote ...

The market for anti-obesity drugs has been growing for a while, but is finally about to take off with the entry of two global ...

Ozempic, initially for type 2 diabetes, has gained popularity for rapid weight loss, leading to a newly reported side effect ...

Indian diabetic population on Human Mixtard concerned on changes in insulin therapy: Nandita Vijayasimha, Bengaluru Thursday, April 24, 2025, 08:00 Hrs [IST] India’s diabetic po ...

Riding on a surge in global demand for its patented obesity and diabetes medicines Ozempic, Wegovy and Rybelsus, ...

Discover what Hollywood stars are saying about Ozempic, the weight-loss drug. From shocking side effects to personal ...

The country’s pharmaceuticals market grew by 8.4 per cent during financial year 2024-25 on the back of major therapies showing positive value growth, according to market research firm Pharmarack.

Tirzepatide and GLP-1 receptor agonists are replacing older treatments, marking a shift in how diabetes and weight loss are managed.

Here’s how Semaglutide, developed by Danish drugmaker Novo Nordisk, is available in India in the form of oral pills under the brand name Rybelsus. Both semaglutide and tirzepatide work by ...